A commentary on ‘Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: an experimental single-arm phase II clinical trial pilot study’

aMedical Research Center, Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, 310000, Hangzhou, China bGenetic Diagnosis Center, The First Hospital of Jilin University, 130021, Changchun, China Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Genetic Diagnosis Center, The First Hospital of Jilin University, 130021, Changchun, China. E-mail address: [email protected] (Y. Jiang). This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0/